Antibiotic therapy in the emergency room: Optimal prescription is indeed the best.


Journal

Infectious diseases now
ISSN: 2666-9919
Titre abrégé: Infect Dis Now
Pays: France
ID NLM: 101775152

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 14 09 2022
revised: 13 01 2023
accepted: 22 01 2023
medline: 8 5 2023
pubmed: 30 1 2023
entrez: 29 1 2023
Statut: ppublish

Résumé

Emergency departments (ED) are pivotal for antibiotic prescription, of which the appropriateness and consequences have rarely been assessed. A retrospective study included patients referred to the ED and hospitalized with an advocated diagnosis of infection. Day-0 (ED initial prescription) and day-2 (reevaluation) antibiotic therapies were graded as optimal (if fully following the guidelines in terms of molecule, dose, and route of administration), adapted (if the prescribed molecule was microbiologically active but not recommended as first-line treatment, or in case of a wrong dose), or inadequate (other situations). The primary endpoint was onset of an unfavorable event (death, transfer to intensive care unit, or re-hospitalization). Prognosis factors associated with survival without unfavorable event were assessed by multivariate analysis. We included 484 patients. Optimal, adapted, and inadequate initial prescriptions concerned 328 (67.8 %), 110 (22.7 %) and 46 (9.5 %) patients respectively. Compared with an optimal prescription, an initial adapted prescription was associated with a poorer prognosis (HR = 1.95, CI95% [1.18-3.22]; p = 0.01). Reevaluation was performed in 436 (90.1 %) patients. After reevaluation, optimal, adapted, and inadequate prescriptions concerned 326 (74.8 %), 64 (14.7 %), and 46 (10.5 %) patients respectively. After reevaluation, and as compared with optimal prescription, inadequate prescription was significantly associated with unfavorable events (HR = 3.52, CI95% [1.42-8.72]; p = 0.003). Antibiotics are frequently prescribed in EDs. Antibiotic prescription has got to be optimal, and not simply adapted, so as to be associated with significant clinical benefit.

Identifiants

pubmed: 36709866
pii: S2666-9919(23)00015-5
doi: 10.1016/j.idnow.2023.104653
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104653

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Auteurs

F Moretto (F)

Infectious Diseases Department, Dijon University Hospital, 14 Paul Gaffarel Street, 21000 Dijon, France. Electronic address: florian.moretto@chu-dijon.fr.

F Catherine (F)

Infectious Diseases Department, Chalon-sur-Saone Hospital, 4 Capitaine Drillien Street, 71200 Chalon-sur-Saone, France.

B Martha (B)

Infectious Diseases Department, Chalon-sur-Saone Hospital, 4 Capitaine Drillien Street, 71200 Chalon-sur-Saone, France.

T Sixt (T)

Infectious Diseases Department, Dijon University Hospital, 14 Paul Gaffarel Street, 21000 Dijon, France.

P Chavanet (P)

Infectious Diseases Department, Dijon University Hospital, 14 Paul Gaffarel Street, 21000 Dijon, France.

M Blot (M)

Infectious Diseases Department, Dijon University Hospital, 14 Paul Gaffarel Street, 21000 Dijon, France; CHU Dijon-Bourgogne, INSERM, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, Dijon, France.

P Ray (P)

Emergency Room Department, Dijon University Hospital, France.

L Piroth (L)

Infectious Diseases Department, Dijon University Hospital, 14 Paul Gaffarel Street, 21000 Dijon, France; CHU Dijon-Bourgogne, INSERM, Université de Bourgogne, CIC 1432, Module Épidémiologie Clinique, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH